Literature DB >> 18228345

Tail vein assay of cancer metastasis.

Michael Elkin1, Israel Vlodavsky1.   

Abstract

The most damaging change during cancer progression is the switch from a locally growing tumor to a metastatic killer. This switch involves numerous alterations that allow tumor cells to complete the complex series of events needed for metastasis. In considering steps required for successful metastasis, extravasation from blood vessels in target organs is regarded as a critical process. Circulating tumor cells arrested in the capillary beds of different organs must invade the endothelial cell lining of blood vessels and degrade its underlying basement membrane in order to escape into the extravascular tissue where they establish metastasis. This unit describes the most common assay applied to evaluate the metastatic potential of blood-borne tumor cells. The protocol is often called "experimental metastasis", distinct from "spontaneous metastasis", where the tumor cells are first allowed to form a primary tumor in the site of injection and then escape into lymphatic or blood circulation. Cultured tumor cells are injected into the tail vein and allowed to circulate. After 12 to 20 days the recipients are euthanized and the lungs are evaluated for the presence of metastatic tumors.

Entities:  

Mesh:

Year:  2001        PMID: 18228345     DOI: 10.1002/0471143030.cb1902s12

Source DB:  PubMed          Journal:  Curr Protoc Cell Biol        ISSN: 1934-2616


  36 in total

1.  Loss of BRMS1 promotes a mesenchymal phenotype through NF-κB-dependent regulation of Twist1.

Authors:  Yuan Liu; Marty W Mayo; Aizhen Xiao; Emily H Hall; Elianna B Amin; Kyuichi Kadota; Prasad S Adusumilli; David R Jones
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

2.  Host b7x promotes pulmonary metastasis of breast cancer.

Authors:  Yael M Abadi; Hyungjun Jeon; Kim C Ohaegbulam; Lisa Scandiuzzi; Kaya Ghosh; Kimberly A Hofmeyer; Jun Sik Lee; Anjana Ray; Claudia Gravekamp; Xingxing Zang
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

3.  Lymphatic biodistribution of polylactide nanoparticles.

Authors:  Eric J Chaney; Li Tang; Rong Tong; Jianjun Cheng; Stephen A Boppart
Journal:  Mol Imaging       Date:  2010-06       Impact factor: 4.488

4.  In vitro and in vivo model systems used in prostate cancer research.

Authors:  David Cunningham; Zongbing You
Journal:  J Biol Methods       Date:  2015

Review 5.  Reviewing and reconsidering invasion assays in head and neck cancer.

Authors:  Ronald C Inglehart; Christina S Scanlon; Nisha J D'Silva
Journal:  Oral Oncol       Date:  2014-10-14       Impact factor: 5.337

6.  Repurposing suramin for the treatment of breast cancer lung metastasis with glycol chitosan-based nanoparticles.

Authors:  Bei Cheng; Feng Gao; Erica Maissy; Peisheng Xu
Journal:  Acta Biomater       Date:  2018-12-05       Impact factor: 8.947

Review 7.  Animal Models of Bone Metastasis.

Authors:  J K Simmons; B E Hildreth; W Supsavhad; S M Elshafae; B B Hassan; W P Dirksen; R E Toribio; T J Rosol
Journal:  Vet Pathol       Date:  2015-05-28       Impact factor: 2.221

8.  Sulfated hexasaccharides attenuate metastasis by inhibition of P-selectin and heparanase.

Authors:  Lubor Borsig; Israel Vlodavsky; Rivka Ishai-Michaeli; Giangiacomo Torri; Elena Vismara
Journal:  Neoplasia       Date:  2011-05       Impact factor: 5.715

9.  Dissemination via the lymphatic or angiogenic route impacts the pathology, microenvironment and hypoxia-related drug response of lung metastases.

Authors:  Roben G Gieling; Richard J Fitzmaurice; Brian A Telfer; Muhammad Babur; Kaye J Williams
Journal:  Clin Exp Metastasis       Date:  2015-06-26       Impact factor: 5.150

10.  Intra-arterial injection to create bone metastasis of prostate cancer in mice.

Authors:  Lin Zhong; Haiyan D Miller; Yongfeng Zhang; Ben Jin; Dongxia Ge; Zongbing You
Journal:  Am J Clin Exp Urol       Date:  2020-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.